Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab

Journal of Vascular and Interventional Radiology

Volumn 12, Issue 7, 2001, Pages 795-805

  Benenati, James ^a   Shlansky Goldberg, Richard ^b   Meglin, Allen ^d   Seidl, Edward ^c  

^a BAPTIST CARDIAC AND VASCULAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d New Hanover Medical Center   (United States)

Author keywords

Abciximab; Reteplase; Thrombolysis; Tissue type plasminogen activator

Indexed keywords

ABCIXIMAB; ALTEPLASE; COLLAGEN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; PLACEBO; PLASMINOGEN ACTIVATOR; RETEPLASE; SODIUM CHLORIDE; STREPTOKINASE; TENECTEPLASE; TIROFIBAN; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD CLOT LYSIS; BLOOD FLOW; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FIBRINOLYTIC THERAPY; FOOD AND DRUG ADMINISTRATION; HUMAN; LEG ISCHEMIA; LUNG EMBOLISM; LUNG RESISTANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED STATES;

EID: 0034933970     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(07)61503-6     Document Type: Review

References (57)

1. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions
2. Intra-arterial reteplase for the treatment of acute limb ischemia
3. Reteplase in the treatment of peripheral arterial and venous occlusions: A pilot study
4. Use of a glycoprotein IIb/IIIa receptor antagonist (abciximab) in peripheral vascular interventions
5. Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis
6. The platelet IIb/IIIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions
7. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis
8. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis
9. Comparison of two different thrombolytic regimens with and without abciximab in ST-elevation myocardial infarction: Observations from the TIMI 14 trial
10. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
11. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature
12. Thrombolysis in the treatment of lower extremity occlusive disease
13. Efficacy and safety of intraarterial local infusion of streptokinase, urokinase, or tissue plasminogen activator for peripheral arterial occlusion: A retrospective review
14. Alteplase as an alternative to urokinase
15. Evolving strategies for thrombolytic therapy of peripheral vascular occlusion
16. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis
17. Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA
18. Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: Lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics
19. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
20. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
21. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings
22. A comparison of reteplase with alteplase for acute myocardial infarction
23. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism
24. Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
25. Role of platelets in arterial thrombosis and the rationale for blockade of platelet GP IIa/IIIb receptors as antithrombotic therapy
26. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
27. Mβ2 receptors: With a review of platelet-leukocyte interactions
28. Pharmacologic differentiation of inhibitors
29. Effects of Integrilin on platelet function in flow models of arterial thrombosis
30. GP IIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
31. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
32. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
33. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
34. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/III blockade in patients undergoing coronary stenting: Results from a multicentre randomized trial
35. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
36. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade
37. Potential role of abciximab in ischemic cerebro-vascular disease
38. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: Preliminary experience
39. Abciximab in acute ischemic stroke: A randomized, doubleblind, placebo-controlled, dose-escalation study
40. Abciximab facilitates the rate and extent of thrombolysis; results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial
41. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 pilot) trial
42. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial
43. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial
44. Intraarterial thrombolysis of lower extremity occlusions: Prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion
45. Augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude
46. Conjunctive platelet glycoprotein IIb/IIIa receptor antagonism and thrombolysis for peripheral arterial thrombosis: Results of the pilot trial Platelet Receptor antibodies in Order to Manage Peripheral arterial Thrombosis (PROMPT)
47. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis
48. ASHP guidelines on quality assurance for pharmacy-Prepared sterile products
49. The efficacy of reteplase in the treatment of thrombosed dialysis venous catheters: A retrospective study
50. Weekly prophylactic urokinase instillation in tunneled central venous access devices
51. Comparative trial of urokinase versus heparin as prophylaxis for central venous ports
52. Partial occlusion of indwelling central venous catheters
53. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
54. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial
55. Local intra-arterial fibrinolytic therapy in patients with stroke: Urokinase versus recombinant tissue plasminogen activator (r-TPA)
56. Neurovascular-penumbral protection in subacute ischemic brain infarction secondary to critical ipsilateral carotid lesion; the role of carotid stenting using the glycoprotein IIb/IIIa inhibitor abciximab